A new trial found that video-assisted thoracic surgery (VATS) significantly reduces in-hospital complications and shortens hospital stays compared to open surgery for early-stage lung cancer patients. VATS, a minimally invasive technique, showed improved outcomes without compromising oncologic results.
Durvalumab plus chemotherapy significantly improved overall survival in patients with extensive-stage small cell lung cancer, with a median survival of 13 months compared to 10.3 months for the control group. The study found that 33.9% of patients receiving durvalumab were alive at 18 months.
A Scottish study shows that combining an autoantibody test with CT imaging can significantly decrease late-stage lung cancer diagnoses and potentially lower lung cancer-specific mortality. The EarlyCDT-Lung Test identifies high-risk individuals, allowing for earlier interventions.
A European lung cancer screening model outperformed a US model in detecting cancers, with 99% of cancers found using the European method compared to 77%. The study found that the model detected more cancers among high-risk patients and had a higher accuracy rate.
A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.
The MYSTIC trial found that patients with STK11 or KEAP1 mutations had poorer outcomes to anti-PD-L1 and anti-CTLA-4 immunotherapies compared to those without these mutations. ARID1A mutations were associated with improved survival in the durvalumab + tremelimumab arm.
The MYSTIC trial found that patients with STK11 or KEAP1 gene mutations in metastatic non-small cell lung cancer experienced poorer overall survival compared to those without these mutations. Additionally, patients with ARID1A mutations in the durvalumab + tremelimumab arm had longer median overall survival rates.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
The bioMILD trial demonstrated that combining low-dose CT screening with a microRNA blood test reduces lung cancer mortality and incidence in high-risk individuals. The study found that participants with positive LDCT and/or miRNA at baseline had a significantly higher lung cancer incidence and overall mortality.
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
Cancer patients who continue smoking after diagnosis have a higher mortality rate and increased risk for second cancer development. The IASLC Declaration recommends screening all cancer patients for tobacco use and advising on tobacco cessation.
A follow-up study reaffirms the effectiveness of low-dose computed tomography (LDCT) in reducing lung cancer mortality. The research found that LDCT can prevent lung cancer deaths or at least delay them for more than a decade, with only 303 patients needed to be screened to prevent one death.
The IASLC has launched a pilot project to develop an innovative technique for improving early lung cancer detection through shared computed tomography images. The project aims to create a globally-accessible environment for analyzing large collections of quality-controlled CT lung cancer images and associated biomedical data.
A study published in the Journal of Thoracic Oncology found that elderly patients with limited-stage small cell lung cancer (LS-SCLC) can benefit from concurrent chemo-radiotherapy, similar to younger patients. The analysis showed comparable survival rates and toxicity between older and younger groups, providing robust evidence for tre...
The IASLC affirms the strength of evidence supporting lung cancer screening, reducing mortality by 26-61% in high-risk populations. The organization recommends implementing global lung cancer screening programs, incorporating multidisciplinary teams and best-practice smoking cessation.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A study published in the Journal of Thoracic Oncology found that active surveillance of lung subsolid nodules can reduce unnecessary surgery and overtreatment. Lung cancers arising from these nodules rarely led to death, suggesting they can be a biomarker for cancer risk.
The International Association for the Study of Lung Cancer (IASLC) has issued a statement paper on liquid biopsy for advanced non-small cell lung cancer, recommending its use for molecular analysis in guiding clinical management. The paper aims to provide general oncologists and clinicians with access to the latest information on liqui...
A study analyzed 154,498 NSCLC and 27,834 SCLC patients who died on or before December 31, 2013, revealing racial-ethnic disparities in end-of-life care quality. Minority patients had higher odds of preventable medical encounters, delayed hospice referral, and aggressive chemotherapy during end-of-life.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
The updated guideline strengthens recommendations for patients with lung adenocarcinoma, recommending testing for ROS1 mutations and multiplexed genetic sequencing panels. The panel also reaffirmed or strengthened existing recommendations, including testing in relapse for EGFR T790M, with some notable changes.
Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival when treated with chemoradiation compared to definitive radiation alone. Treatment with concurrent or sequential CRT was associated with a 33% reduction in the risk of death.
A 12-week physical and psycho-social intervention improved functional capacity in advanced lung cancer patients, while also enhancing their quality of life. The study's findings suggest that exercise interventions can be a beneficial approach for these patients, reducing the burden on caregivers and improving overall well-being.
A community-based intervention called c-CARE improved cancer literacy and reduced disparate lung cancer outcomes among minority communities. The study found that participants showed increased knowledge and self-efficacy for lung cancer screening, but not perceived susceptibility.
A study analyzing over 1.1 million NSCLC cases found significant disparities in survival rates based on race and socioeconomic factors such as education level and income. Patients of Asian and Hispanic backgrounds had better overall survival rates compared to Whites and Blacks.
A study integrating smoking cessation programs with low-dose CT lung cancer screenings found that this approach can decrease mortality rates while being relatively cost-effective. The research suggests that adding a robust smoking cessation intervention to an organized LDCT screening program could result in significantly fewer deaths, ...
A study published at the International Association for the Study of Lung Cancer (IASLC) conference found that biopsy specimens are a reliable material for evaluating DLL3 expression in small cell lung cancer. High levels of DLL3 expression were correlated with poor survival trends, smoking history, and neuroendocrine differentiation.
A study published in the IASLC 18th World Conference on Lung Cancer found that early specialist palliative care for recently diagnosed malignant pleural mesothelioma (MPM) patients does not impact quality of life. Researchers concluded that there is no role for routine early referral to palliative care, regardless of symptoms.
Researchers confirmed IASLC's proposed criteria for uncertain resection margin status (R(un)) have a prognostic value between R0 and R1. The study analyzed data from 14,712 patients and evaluated the impact of various factors on survival.
Researchers found that treating stage II and III non-small cell lung cancer (NSCLC) patients with chemotherapy based on their specific BRCA1 expression levels did not increase overall survival rates. However, BRCA1 expression levels were found to be prognostic, and individualized treatment could achieve different outcomes.
Lung cancer clinical trials have complex requirements that act as a barrier to development and patient enrollment. A retrospective study found an increase in eligibility criteria for medical therapy trials, particularly for cardiac, concurrent medications, and immunotherapy-related treatments.
The IASLC published a comprehensive summary of the year's key developments in thoracic oncology, covering prevention, early detection, pathology, staging, surgery, adjuvant therapy, radiotherapy, and immunotherapy. The publication highlights significant progress in small cell lung cancer and malignant mesothelioma.
A retrospective study found that treatment improved overall survival in elderly patients with early-stage esophageal cancer. Surgery and local therapies such as chemoradiation showed significantly improved five-year overall survival rates compared to observation, with a median age of 84 years.
A new study has found that radiotherapy for invasive breast cancer increases the risk of developing second primary lung cancer. The research, conducted in Taiwan, involved analyzing data from over 986,000 patients with breast cancer between 2000 and 2010. The results showed a significant increase in lung cancer incidence among women wh...
A study found that elderly non-small cell lung cancer (NSCLC) patients experiencing definitive radiation had a lower incidence of esophagitis compared to younger patients. The study, published in the Journal of Thoracic Oncology, showed an inverse correlation between age and rate of esophagitis for both grade levels.
According to a study published in Journal of Thoracic Oncology, advanced stage Non-Small Cell Lung Cancer (NSCLC) patients receiving standard of care treatment have significantly longer overall survival rates compared to those not receiving treatment. This trend is observed across various stages of the disease.
A study analyzing 740 early-stage NSCLC patients treated with SBRT found that Squamous Cell Carcinoma (SqCC) has a significantly higher rate of local failure compared to other histological subtypes. SqCCs are more resistant to SBRT, which may require treatment optimization based on histological subtype.
French researchers report harmonization study on PD-L1 immunohistochemistry testing in NSCLC. Durvalumab shows clinical activity and well-tolerability in heavily-pretreated patients with NSCLC. Patients receiving pembrolizumab report better quality of life than those on chemotherapy.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
Public health advocates from around the world are using various tactics to reduce tobacco company influence, including pension fund reform and smoke-free legislation. Efforts have shown positive impacts on public health, such as a 13% decrease in all-cause mortality in Ireland.
Researchers and patient advocates emphasize the importance of new care models in combating lung cancer. Dr. Laurie Gaspar discusses the benefits of shared decision-making and Patient Decision Aids, while Dr. Raymond Osarogiagbon highlights the effectiveness of Center of Excellence programs in underserved areas.
A study of 101 advanced lung cancer patients found that hybrid capture-based next-generation sequencing (HC-based NGS) identified clinically actionable genomic alterations (GAs) in 50% of patients, leading to changes in treatment strategy. The overall response rate to targeted therapies was 65%, with median survival not yet reached.
A randomized controlled trial found that preoperative high-intensity interval training improved aerobic performance in patients with operable non-small cell lung cancer. However, it did not significantly reduce postoperative complications or mortality rates.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
Researchers developed liquid biopsies to detect EGFR mutations in urine, plasma, and blood samples. The tests showed high sensitivity and specificity for identifying patients suitable for targeted treatment and predicting cancer recurrence.
A Swiss analysis found that treating Nivolumab only to patients with positive PD-L1 tests compared to DOC or all patients with NIV is more cost-effective, with ICERs below the WTP threshold. Treating only patients with ?1% or ?10% PD-L1+ with NIV also results in improved cost-effectiveness.
The College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology announced a revised evidence-based guideline for molecular testing in lung cancer patients. The guidelines aim to improve patient selection and targeted therapies.